Юперіо (сакубітрил/валсартан) — Пацієнти та безпека

Хто з пацієнтів може отримувати ЮПЕРІО? 

Посилання 
1. Інструкція для медичного застосування Юперіо: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument&query=%DE%EF%E5%F0%B3%EE. 3. Vaduganathan M, Claggett BL, Greene SJ, et al. Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiol. 2021;6(12):1415-1423. doi:10.1001/jamacardio.2021.3651. 4. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensinneprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655. 6. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure [published correction appears in N Engl J Med. 2019;380(11):1090]. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851. 8. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;S0735-1097(23):05429-3. doi:10.1016/j.jacc.2023.04.019. 9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines [published correction appears in J Am Coll Cardiol. 2023;81(15):1551]. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012. 10. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835-1878. doi:10.1016/j.jacc.2023.03.393